Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone maintains a Buy rating on ADMA Biologics (NASDAQ:ADMA) and raises the price target from $12 to $14.
June 20, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Anthony Petrone maintains a Buy rating on ADMA Biologics and raises the price target from $12 to $14.
The Buy rating and increased price target from a reputable analyst at Mizuho is likely to boost investor confidence in ADMA Biologics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100